HRS-7058 + SHR-A2102 + BP102

HRS-7058 + SHR-A2102 + BP102 is an investigational combination therapy being developed by Shandong Suncadia Medicine (a subsidiary of Jiangsu Hengrui Pharmaceuticals) for the treatment of advanced malignant solid tumors. The regimen includes **HRS-7058**, a selective small molecule inhibitor of extracellular signal-regulated kinases 1 and 2 (**ERK1/2**), which are key components of the MAPK/ERK signaling pathway often dysregulated in cancer. **SHR-A2102** is an antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody targeting **Nectin-4** conjugated to a potent cytotoxic payload, typically a topoisomerase I inhibitor. **BP102** is a biosimilar of **bevacizumab**, a monoclonal antibody that binds to vascular endothelial growth factor A (**VEGF-A**) to inhibit angiogenesis. This multi-pronged approach aims to achieve synergistic anti-tumor activity by simultaneously targeting intracellular signaling, cell-surface antigens, and the tumor microenvironment. It is currently being evaluated in Phase II clinical trials for patients with advanced solid tumors who have progressed on standard therapies.